{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"44","value":"19"}]}],"title":"NRM at 1 Year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13","upperLimit":"55","value":"29"}]}],"title":"NRM at 3 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Non relapse mortality, defined as the percentage of deaths not attributable to disease relapse or progression at 1 year and at 3 years.","dispersionType":"95% Confidence Interval","groups":[{"description":"Fludarabine Busulfan chemotherapy regimen (Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.\n\nFludarabine/Busulfan x 4 days:\n\nFludarabine: 40 mg/m2/day, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.\n\nBusulfan: 3.2 mg/kg IV daily over 4 hours on days -5, -4, -3, and -2.\n\nThe Fludarabine shall be administered prior to the Busulfan each day.","id":"OG000","title":"Flu-Bu4"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"Non Relapse Mortality (NRM) at 1 Year and 3 yearsThe Percentage of Deaths Not Attributable to Disease Relapse or Progression","type":"SECONDARY","unitOfMeasure":"percentage of deaths"}